title: Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma.
abstract: BACKGROUND
  Even though Hodgkin lymphoma is a highly curable disease, some of the patients have either a refractory disease or experience a relapse following a successful primary therapy. Durable responses and remissions in patients with relapsed or refractory disease may be achieved in approximately one-half with salvage chemotherapy followed by high dose chemotherapy (HDT) and autologous hematopoietic cell rescue (SCT). On the other hand, patients who relapse after HDT and autologous SCT or those who have failed at least two prior multi-agent chemotherapy regimens and are not candidates for HDT have limited treatment options.
  
  
  CONCLUSIONS
  A new treatment option in this population is an immunotoxin Brentuximab vedotin composed of a CD30 directed antibody linked to the antitubulin agent monomethyl auristatin E. It has demonstrated a substantial effectiveness and an acceptable toxicity. In the pivotal study, the overall response rate was 75% with 34% of complete remissions. The median durations of response were 20.5 and 6.7 months for those with complete remission and all responding patients, respectively. The median overall survival was 40.5 months (3-years overall survival 54%) and the median progression-free survival 9.3 months. The most common non-hematologic toxicities were peripheral sensory neuropathy, nausea, and fatigue while the most common severe side effects were neutropenia, thrombocytopenia, anemia, and peripheral sensory neuropathy.
authors.affiliation: Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
authors.forename: Barbara Jezersek
authors.initials: BJ
authors.lastname: Novakovic
keywords: Hodgkin lymphoma; new treatment option; relapsed and refractory; toxicity; treatment effectiveness
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2197-203
references.pmid: 22547596
references.citation: Clin Neurol Neurosurg. 2012 Dec;114(10 ):1335-7
references.pmid: 22472351
references.citation: Blood. 2012 Aug 16;120(7):1470-2
references.pmid: 22786877
references.citation: Br J Haematol. 2009 May;145(3):369-72
references.pmid: 19344403
references.citation: J Clin Oncol. 2013 Feb 1;31(4):456-60
references.pmid: 23248254
references.citation: Haematologica. 2013 Aug;98 (8):1232-6
references.pmid: 23645687
references.citation: Cancer Treat Rev. 2014 Apr;40(3):457-64
references.pmid: 24095205
references.citation: Blood. 2012 Jun 28;119(26):6379-81
references.pmid: 22611160
references.citation: Bone Marrow Transplant. 2014 May;49(5):599-606
references.pmid: 24442246
references.citation: Br J Haematol. 2014 Jan;164(1):39-52
references.pmid: 24117159
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2183-9
references.pmid: 22454421
references.citation: Haematologica. 2010 Sep;95(9):1496-502
references.pmid: 20460643
references.citation: N Engl J Med. 2015 Jan 22;372(4):311-9
references.pmid: 25482239
references.citation: Clin Lymphoma. 2004 Sep;5(2):110-5
references.pmid: 15453926
references.citation: Haematologica. 2013 Apr;98 (4):611-4
references.pmid: 23065511
references.citation: Blood. 2012 May 3;119(18):4123-8
references.pmid: 22371887
references.citation: Lancet Oncol. 2013 Dec;14 (13):1348-56
references.pmid: 24239220
references.citation: N Engl J Med. 1992 Nov 19;327(21):1478-84
references.pmid: 1383821
references.citation: Biol Blood Marrow Transplant. 2013 Mar;19(3):410-7
references.pmid: 23128322
references.citation: Blood. 2012 Jul 19;120(3):560-8
references.pmid: 22510871
references.citation: Oncologist. 2012;17 (8):1073-80
references.pmid: 22855426
references.citation: Leuk Lymphoma. 2007 May;48(5):881-4
references.pmid: 17487730
references.citation: Bone Marrow Transplant. 2004 May;33(10):1015-23
references.pmid: 15048145
references.citation: Ann Oncol. 1994 Nov;5(9):817-20
references.pmid: 7531487
references.citation: Clin Cancer Res. 2012 Jan 1;18(1):248-55
references.pmid: 22080439
references.citation: J Clin Oncol. 2002 Jan 1;20(1):221-30
references.pmid: 11773173
references.citation: Br J Haematol. 2008 Apr;141(1):3-13
references.pmid: 18279457
references.citation: N Engl J Med. 2010 Nov 4;363(19):1812-21
references.pmid: 21047225
references.citation: Clin Cancer Res. 2010 Feb 1;16(3):888-97
references.pmid: 20086002
references.citation: Blood. 2005 Aug 15;106(4):1473-8
references.pmid: 15870180
references.citation: J Clin Oncol. 1997 Feb;15(2):528-34
references.pmid: 9053474
references.citation: Am J Hematol. 2010 May;85(5):320-4
references.pmid: 20229590
references.citation: J Clin Oncol. 1987 Jan;5(1):27-37
references.pmid: 2433409
references.citation: Leuk Lymphoma. 2012 Nov;53(11):2283-6
references.pmid: 22424602
references.citation: Blood. 2012 May 3;119(18):4129-32
references.pmid: 22343727
references.citation: Ann Oncol. 2002 Oct;13(10):1650-5
references.pmid: 12377656
references.citation: Blood. 2015 Feb 19;125(8):1236-43
references.pmid: 25533035
references.citation: Drugs R D. 2014 Mar;14 (1):9-11
references.pmid: 24493291
references.citation: Bone Marrow Transplant. 2004 Jun;33(12):1225-9
references.pmid: 15094747
references.citation: Bone Marrow Transplant. 2006 Feb;37(3):283-8
references.pmid: 16327815